Could Singapore become the next global biotech hub?

Despite planting seeds for decades, Singapore has yet to blossom into a global hub for biotechs. A new wave of international biopharmas setting up shop in the country and an influx of sophisticated, global biotech investors could change that.  

Since the 1990s, Singapore has positioned itself as a world-class manufacturing hub, and has sought to build the research and manufacturing infrastructure to establish the biomedical sector as a pillar of growth for the country. That strategy received a jolt in 2000 with the launch of the country’s biomedical strategy, which established the R&D and biomanufacturing hub Biopolis, the Bio*One Capital fund to invest in domestic and overseas life sciences and biomanufacturing companies, and an initiative to attract scientists to Singapore as well as build talent locally...